Last reviewed · How we verify

Valsartan and Sacubitril

University Hospital Ostrava · FDA-approved active Small molecule Quality 5/100

Valsartan and Sacubitril is a Small molecule drug developed by University Hospital Ostrava. It is currently FDA-approved. Also known as: Entresto, ATC C09DX04.

At a glance

Generic nameValsartan and Sacubitril
Also known asEntresto, ATC C09DX04
SponsorUniversity Hospital Ostrava
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Valsartan and Sacubitril

What is Valsartan and Sacubitril?

Valsartan and Sacubitril is a Small molecule drug developed by University Hospital Ostrava.

Who makes Valsartan and Sacubitril?

Valsartan and Sacubitril is developed and marketed by University Hospital Ostrava (see full University Hospital Ostrava pipeline at /company/university-hospital-ostrava).

Is Valsartan and Sacubitril also known as anything else?

Valsartan and Sacubitril is also known as Entresto, ATC C09DX04.

What development phase is Valsartan and Sacubitril in?

Valsartan and Sacubitril is FDA-approved (marketed).

Related